Viral Vectors and Plasmid DNA Manufacturing Market Size US$ 1.3 bn by 2027

According to Precedence Research, the global viral vectors & plasmid DNA manufacturing market size was valued at USD 319.01 million in 2019 and expected to reach over USD 1.3 billion by 2027

The global viral vectors & plasmid DNA manufacturing market is growing at a compound annual growth rate (CAGR) of 14.08% during period 2020 to 2027.

Growth Factors

Advent of advanced therapies including gene therapy that employs the use of various viral and non-viral vectors has paved a way for the treatment of several heritable and acquired diseases that previously lacked effective treatment modalities. Post the approval of Novartis’s Zolgensma, drug developers have begun considering these new areas of treatment as a sustainable business model. Thus, the speculated accelerating investment is expected to drive the growth.

High transfection efficiency, effective gene delivery, and stable gene expression have made viral vectors a preferred choice for gene transfer. The rising preference for viral vectors in gene transfer is evident by the increase in registration of clinical trials on viral vector-mediated gene therapy. In the first quarter of 2019, around 372 clinical trials were registered that involved vector-mediated gene therapy production.

Considering the efficiency and clinical benefits of Advanced Therapies Medicinal Products (ATMPs), various market stakeholders are constantly designing strategies to overcome the existing challenges and spur ATMPs usage. Moreover, the recent announcement by the Food and Drug Administration (FDA) commissioner about improving regulatory support for the cell and gene therapy sector to keep up the pace with the clinical progress has substantiated the anticipated success of ATMPs.

Get Sample Pages of Report for more Understanding@ https://www.precedenceresearch.com/sample/1012

Vector manufacturing is one of the most complex and resource-intensive processes in ATMPs manufacturing. In October 2019, GE Healthcare Life Sciences launched FlexFactory single-use biomanufacturing platform-based KUBio box as a fully-integrated and flexible biomanufacturing environment to affectively address the aforementioned challenge and speed-up the development of viral vector-based gene therapies.

However, expensive and highly regulated processes for vector production in large quantities required for large-scale clinical trials are the key challenges cited by industry experts. Moreover, the shortfall of expertise in terms of scale, complexities, and quality assurance for vector production has hampered in-house manufacturing to a certain extent. The proliferation of contract manufacturers has effectively addressed the above-articulated manufacturing challenges by offering a wide array of services for vector manufacturing, thus driving the market growth.

Scope of the Report

A recent study by Precedence Research on the viral vectors and plasmid DNA manufacturing market offers a forecast for 2020 and 2027. The study analyzes crucial trends that are currently determining the growth of the viral vectors and plasmid DNA manufacturing market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of viral vectors and plasmid DNA manufacturing. The study also provides the dynamics that are responsible for influencing the future status of the viral vectors and plasmid DNA manufacturing market over the forecast period.

A detailed assessment of the viral vectors and plasmid DNA manufacturing market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the viral vectors and plasmid DNA manufacturing market along with their product portfolio enhances the reliability of this comprehensive research study.

In this study, the years considered to estimate the market size of viral vectors and plasmid DNA manufacturing are as follows:

· History Year: 2016-2019

· Base Year: 2019

· Estimated Year: 2020

· Forecast Year 2020 to 2027

Report Summary

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the viral vectors and plasmid DNA manufacturing market across the globe.

A comprehensive estimate on the viral vectors and plasmid DNA manufacturing market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of viral vectors and plasmid DNA manufacturing during the forecast period. Price point comparison by region with global average price is also considered in the study.

Market Size Evaluation

The viral vectors and plasmid DNA manufacturing market has been analyzed for each market segment in terms of volume (kilo tons) and value (US$ Bn).

Market estimates at global and regional levels for viral vectors and plasmid DNA manufacturing are available in terms of “US$ Bn” for value and in “kilo tons” for volume. A Y-o-Y growth contrast on prominent viral vectors and plasmid DNA manufacturing market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global Viral vectors and plasmid DNA manufacturing market.

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1012

Inspected Assessment on Regional Segments

Key sections have been elaborated in the viral vectors and plasmid DNA manufacturing market report, which have helped deliver projections on regional markets. These chapters include regional macros (political economic and business environment outlook), which are expected to have a momentous influence on the growth of viral vectors and plasmid DNA manufacturing market during the forecast period.

Country-specific valuation on demand for viral vectors and plasmid DNA manufacturing has been offered for each regional market, along with market scope estimate sand forecasts, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

Segmentation

By Vector Type

Adenovirus
Plasmid DNA
Lentivirus
Retrovirus
AAV
Others

By Application

Gene Therapy
Antisense &RNAi
Cell Therapy
Vaccinology

By Workflow

Upstream Processing

Vector Recovery/Harvesting
Vector Amplification & Expansion

Downstream Processing

Fill-finish
Purification

By End-User

Biopharmaceutical and Pharmaceutical Companies
Research Institutes

By Disease

Genetic Disorders
Cancer
Infectious Diseases
Others

By Geography

North America

U.S.
Canada

Europe

U.K.
Germany
France

Asia Pacific

China
India
Japan
South Korea

Rest of the World

In-Depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of viral vectors and plasmid DNA manufacturing, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of viral vectors and plasmid DNA manufacturing has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the viral vectors and plasmid DNA manufacturing market.

Some of the significant players in the viral vectors & plasmid DNA manufacturing market include:

Novasep
Aldevron
MerckWaismanBiomanufacturing
Creative Biogene
The Cell and Gene Therapy Catapult
Cobra Biologics
uniQure N.V.
Addgene
FUJIFILM Holdings Corporation
Oxford Biomedicaplc
Takara Bio Inc.

Buy This Premium Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1012

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2020-2027
7.1.1. Adenovirus
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Lentivirus
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. AAV
7.1.5.1. Market Revenue and Forecast (2016-2027)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2016-2027)

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2020-2027
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Antisense &RNAi
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Vaccinology
8.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2020-2027
9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Downstream Processing (Fill-finish, Purification)
9.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2020-2027
10.1.1. Biopharmaceutical and Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2020-2027
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Cancer
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.5. Market Revenue and Forecast, by Disease (2016-2027)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.7. Market Revenue and Forecast, by Disease (2016-2027)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.9. Market Revenue and Forecast, by Disease (2016-2027)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.5. Market Revenue and Forecast, by Disease (2016-2027)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.7. Market Revenue and Forecast, by End-User (2016-2027)
12.2.8. Market Revenue and Forecast, by Disease (2016-2027)
12.2.8.1. Market Revenue and Forecast, by Raw Material (2016-2027)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.9.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.9.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.10. Market Revenue and Forecast, by End-User (2016-2027)
12.2.11. Market Revenue and Forecast, by Disease (2016-2027)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.12.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.12.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.12.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.13. Market Revenue and Forecast, by Disease (2016-2027)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.14.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.14.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.14.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.15. Market Revenue and Forecast, by Disease (2016-2027)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.5. Market Revenue and Forecast, by Disease (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.7. Market Revenue and Forecast, by Disease (2016-2027)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.9. Market Revenue and Forecast, by Disease (2016-2027)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.10.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.10.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.10.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.10.5. Market Revenue and Forecast, by Disease (2016-2027)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.11.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.11.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.11.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.11.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.7. Market Revenue and Forecast, by Disease (2016-2027)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.9. Market Revenue and Forecast, by Disease (2016-2027)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.10.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.10.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.10.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.10.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.11.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.11.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.11.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.11.5. Market Revenue and Forecast, by Disease (2016-2027)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.5. Market Revenue and Forecast, by Disease (2016-2027)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.7. Market Revenue and Forecast, by Disease (2016-2027)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.8.5. Market Revenue and Forecast, by Disease (2016-2027)

Chapter 13. Company Profiles

13.1. Novasep
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aldevron
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck Waisman Biomanufacturing
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Cell and Gene Therapy Catapult
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cobra Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. uniQure N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Addgene
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Oxford Biomedicaplc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Takara Bio Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Buy This Premium Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1012

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace amp; defense, among different ventures present globally. We endeavor to give our clients latest insights on upcoming technologies, new developing markets, dynamically changing business conditions and most recent business-driven applications. These insights help our clients to take informed decisions for their business growth.

Contact Us

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: [email protected]

Follow Us

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/Precedence-Research-105885977867944

https://twitter.com/PrecedenceR